Clinical trials: Nash
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Healthy Volunteers
Multiple Ascending Dose and DDI Study
Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design.
- Trial name
- NCT03031119
- Testing
- PF-06835919, atorvastatin
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Pfizer
Fatty Liver
Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver
this is a prospective, interventional, open-label, randomized study on the efficacy of omega 3 fatty acids supplementation in Egyptian children with non-alcoholic fatty liver disease who had been selected from nutrition and…
- Trial name
- omega 3 (NCT04281121)
- Testing
- omega 3 fatty acids
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Non-alcoholic Steatohepatitis
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.
- Trial name
- NCT05668936
- Testing
- Cotadutide, Moxifloxacin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, NASH - Nonalcoholic Steatohepatitis
Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH
The primary objective of this study is to assess efficacy of intragastric balloon for weight loss in obese patients who also concurrently have NASH.
- Conditions
- Obesity, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- NCT03538236
- Testing
- Intragastric balloon, Lifestyle intervention
- Sponsor
- Johns Hopkins University
NAFLD
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity which can progress to deadly complications like end-stage liver disease and hepatocellular carcinoma.
- Trial name
- NCT04861571
- Testing
- Dietary intervention with very low calorie diet (VLCD), Control Arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Fatty Liver, Nonalcoholic
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Study question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective…
- Trial name
- NCT06117137
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Non-Alcoholic Fatty Liver Disease
Interval Training Versus Electro Acupuncture on Liver Functions in Patients With Non-alcoholic Fatty Liver Disease
in this study, the investigators compare the effect of interval training exercise and electroacupuncture on liver functions in non-alcoholic fatty liver disease patients
- Trial name
- NCT03936803
- Testing
- aerobic interval training exercise ., electro acupuncture
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
NASH, Cirrhosis, Liver
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical…
- Trial name
- NCT05500222
- Testing
- Resmetirom
- Where
- 141 sites in United States, Belgium and 7 more
- Volunteers
- 845 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
- Trial name
- REVERSE (NCT03439254)
- Testing
- Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg)
- Where
- 192 sites in United States, Australia and 10 more
- Volunteers
- 919 people
- Sponsor
- Intercept Pharmaceuticals
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease
The purpose of this research study is to find out about the usefulness of mindfulness for weight loss and improvement of physical and mental health in people who have non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
- Trial name
- NCT05130346
- Testing
- Mindfulness Based Stress Reduction (MBSR)
- Where
- United States
- Sponsor
- Virginia Commonwealth University
NASH
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human…
- Trial name
- NCT03187496
- Testing
- Midazolam, Caffeine, Rosuvastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
NAFLD, Pre-diabetes
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant systems. This state is frequently associated with chronic diseases like obesity, insulin resistance, metabolic syndrome and hepatic…
- Trial name
- NCT02051842
- Testing
- Metadoxine
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
NASH
HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.
- Trial name
- NCT05632861
- Testing
- HuHuangLianzonggan capsule
- Where
- 20 sites in China
- Volunteers
- 76 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Chronic Kidney Diseases, Fatty Liver
Perirenal Fats of Chronic Kidney Disease in Patients With Fatty Liver Disease.
Exploring the association of perirenal fat thickness assessed by MRI in CKD patients with FLD.
- Trial name
- NCT06433388
- Testing
- MRI
- Volunteers
- 70 people
- Sponsor
- Assiut University
Obesity, Obesity, Abdominal
Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD
This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in…
- Conditions
- Obesity, Obesity, Abdominal, NAFLD
- Trial name
- BRAVO (NCT05647915)
- Testing
- Berberine plus lifestyle intervention
- Where
- China
- Volunteers
- 337 people
- Sponsor
- China National Center for Cardiovascular Diseases
NASH - Nonalcoholic Steatohepatitis, NAFLD
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
A multi-centre randomised controlled trial to determine the implementation and health care cost of LiverMultiScan vs. routine methodical assessment (standard care) of Non-alcoholic fatty liver disease (NAFLD) across several…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, Metabolic Syndrome
- Trial name
- RADIcAL1 (NCT03289897)
- Testing
- LiverMultiScan
- Where
- 11 sites in Germany, Netherlands and 2 more
- Volunteers
- 801 people
- Sponsor
- Perspectum
Non Alcoholic Fatty Liver Disease
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
The aim of the current study is to evaluate the association of fatty liver severity and endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients and to find the impact of statin treatment compared to usual care…
- Trial name
- NCT01987310
- Testing
- atorvastatin, lifestyle counseling
- Where
- Israel
- Sponsor
- Sheba Medical Center
Non-Alcoholic Fatty Liver Disease
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT06863376
- Testing
- Carbocysteine 375 MG, Physical activity, walking, and calorie restriction
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.